Clinical Trial

A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 17, 2024 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
To observe and evaluate the efficacy and safety of adebrelimab combination chemotherapy regimen in the perioperative treatment of surgically resectable gastric cancer/adenocarcinoma of the gastroesophageal junction.
Trial Details
NCT Number NCT06506292
Lead Sponsor Tianjin Medical University Cancer Institute and Hospital
Conditions Adebrelimab (SHR-1316), XELOX, GC/GEJC
Enrollment 25 participants
Start Date 2024-07-01
Primary Completion 2026-08-01 (estimated)
Study Completion 2027-08-01 (estimated)
Updated on ClinicalTrials.gov 2024-07-17